Targeting KRAS G12D Mutation: Breakthrough Application of HLA-A*11:01-Restricted Tetramer-PE in Tumor Immunotherapy Research

The MHC HLA-A*11:01/VVVGADGVGK KRAS G12D Tetramer-PE is a rigorously validated high-sensitivity detection reagent, specifically designed for the precise identification and quantification of neo-antigen-specific CD8+ T cells targeting the KRAS G12D oncogenic mutation in human samples.

  • Recent Advances
  • Product Information
Recent Advances

Product Overview

The MHC HLA-A*11:01/VVVGADGVGK KRAS G12D Tetramer-PE is a rigorously validated high-sensitivity detection reagent specifically designed for the precise identification and quantification of KRAS G12D neoantigen-specific CD8+ T cells in human samples. Utilizing optimized tetramer technology, it provides a reliable tool for tumor immunology research.

 

Core Technical Advantages

 

Precision Specificity Recognition

 

Strictly matches HLA-A*11:01 allele

Specifically recognizes the KRAS G12D mutation epitope (VVVGADGVGK)

Excludes cross-reactivity with wild-type KRAS

 

Outstanding Detection Performance

 

PE labeling delivers ultra-high signal-to-noise ratio

Detects rare T cells with frequencies as low as 0.001%

Stable tetramer structure ensures reproducible experimental results

 

Comprehensive Solution

 

Suitable for various sample types (PBMC, TIL, tumor tissue)

Compatible with multicolor flow cytometry panels

Supports cell sorting for subsequent research

 

Main Application Areas

 

Tumor Immunology Research

 

Detection of KRAS G12D mutation-specific T cells

Analysis of T cell functional states (exhaustion, memory subsets)

Monitoring immune responses in tumor microenvironment

 

Immunotherapy Development

 

Quality control of TCR-T cell therapy products

Evaluation of neoantigen vaccine immunogenicity

Monitoring efficacy of immune checkpoint inhibitors

 

Translational Medicine Research

 

Immune monitoring in cancer patients

Development of therapeutic response biomarkers

Research on drug resistance mechanisms

 

Experimental Protocol Features

 

Standardized Process

 

Ready-to-use reagent with simple operation

Optimized staining protocol, completed in 30-60 minutes

Strict control settings ensure reliable results

 

Professional Technical Support

 

Detailed experimental protocols and troubleshooting guides

Personalized panel design recommendations

Support from a professional technical team

 

Product Specifications

 

Item Specification
Storage Condition Store at 2-8°C protected from light
Size 100 tests
Purity >95%
Compatible Samples Human cells

 

Why Choose Us

 

Stringent QC: Each batch is functionally validated

Exceptional Performance: High sensitivity for rare T cell detection

Professional Support: Comprehensive technical support from expert team

Complete Solution: End-to-end solution from detection to analysis

 

```

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience
Nanjing UA Biotechnology Co., Ltd. Email:order@ua-bio.com Phone:+86-25-56221161
公众号
Product Information
The Last The Next